同和药业(300636) - 同和药业调研活动信息

Group 1: Export Business - The company has focused on expanding its export business in regulated markets such as the EU, North America, Japan, and South Korea, with export revenue accounting for over 85% of total revenue from 2017 to 2019, reaching 92% in 2019 [1] - The company is also actively exploring emerging markets in South America, Africa, and other regions, maintaining close relationships with new market clients [2] Group 2: Production Capacity - Currently, the first plant has 11 active API workshops, with an additional workshop under renovation, expected to generate sales revenue of 700-800 million [2] - The second plant is designed with 15 synthesis workshops and 2 formulation workshops, planned to be built in three phases, with the first phase expected to be operational in 2021 [2] Group 3: Product Development - The company has strategically planned its product development based on future growth needs, customer demands, and its capabilities, expanding its product categories beyond five major types to include new varieties in anticoagulants, gout treatment, diabetes, dermatitis, and anemia [3] - Currently, there are 26 API products in production and development, covering several global bestsellers, which helps mitigate operational risks associated with single products [3] Group 4: Market Position and Competition - The company has established a competitive position in the market, with core products like Rebaudioside A, Gabapentin, Celecoxib, and Diclofenac holding significant market shares in their respective segments [3] - The company has developed unique expertise in high-purity products, particularly in the Japanese market, which has the highest standards for product purity and quality [3] Group 5: Impact of COVID-19 - The company's operations have been minimally affected by the COVID-19 pandemic, with some impact on logistics and transportation costs [4] Group 6: Shareholder Activity - The major shareholder, Ningbo Jinghui Venture Capital Partnership, reduced its stake to distribute shares among individual partners, selling a total of 3,820,000 shares before the 2019 annual equity distribution plan [4] - From May 25 to June 16, 2020, the shareholder further reduced its stake by 3,027,040 shares, with 28.12% sold through centralized bidding and 71.88% through block trading, primarily to distribute shares among partners and their relatives [5]